TCM
DNTH icon

Tekla Capital Management’s Dianthus Therapeutics DNTH Stock Holding History

Tekla Capital Management’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-12,027
Closed -$1.51M – 205
2020
Q4 		$1.51M Hold
12,027
– – 0.05% 168
2020
Q3 		$1.31M Hold
12,027
– – 0.05% 169
2020
Q2 		$1.45M Buy
12,027
+10,980
+1,049% +$1.55M 0.06% 180
2020
Q1 		$105K Hold
1,047
– – ﹤0.01% 209
2019
Q4 		$254K Hold
1,047
– – 0.01% 204
2019
Q3 		$172K Buy
+1,047
New +$199K 0.01% 184

Other funds holding DNTH

TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Tekla Capital Management's DNTH Position: Q1 2021 in Review

Tekla Capital Management sold out of Dianthus Therapeutics (DNTH) in Q1 2021, closing a stake of 12,027 shares — an estimated $1.51M sold.

Tekla Capital Management first reported a position in DNTH in Q3 2019 and held it in 6 quarters. The position peaked at $1.51M in Q4 2020. 90 funds tracked by Wall St. Rank hold DNTH as of Q1 2021.

  • Tekla Capital Management reported no remaining Dianthus Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Tekla Capital Management sold 12,027 Dianthus Therapeutics shares in Q1 2021, an estimated $1.51M.
  • Tekla Capital Management first reported a position in Dianthus Therapeutics in Q3 2019 and held it in 6 quarters.
  • Tekla Capital Management's Dianthus Therapeutics position peaked at $1.51M in Q4 2020.
  • 90 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q1 2021.

Based on Tekla Capital Management's 13F filing for Q1 2021, filed 14 May 2021.